Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management

American Journal of Hematology

Volumn 86, Issue 12, 2011, Pages 1017-1026

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 1480; BMS 911543; CYT 387; DANAZOL; EVEROLIMUS; FLUOXYMESTERONE; GIVINOSTAT; HEMOGLOBIN; HYDROXYUREA; INTERLEUKIN 6; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LESTAURTINIB; LY 2784544; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; RUXOLITINIB; SAR 302503; SB 1518; TECHNETIUM 99M; TESTOSTERONE ENANTATE; TG 101348; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XL 019;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; BLAST CELL; BONE MARROW; BONE MARROW SUPPRESSION; BONE PAIN; CANCER SCREENING; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CREATININE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM PLUS; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HYPOTENSION; KARYOTYPE; LEUKOCYTE; LIVER FUNCTION TEST; LIVER TOXICITY; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPHTHISIC ANEMIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEUROPATHY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RISK ASSESSMENT; SEPTIC SHOCK; SIDE EFFECT; SPLENECTOMY; SPLENOMEGALY; STOMATITIS; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRILIZATION; VOMITING; WITHDRAWAL SYNDROME;

ABNORMAL KARYOTYPE; BONE MARROW; DECISION TREES; DIAGNOSIS, DIFFERENTIAL; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY MYELOFIBROSIS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 81355147194     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22210     Document Type: Article

References (89)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
3. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
4. Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011; 25: 1219-1220.
5. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25: 1200-1202.
6. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients. Leukemia, in press.
7. Raza SS, viswanatha D, Erickson L, et al. TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol, in press.
8. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med 2011; 364: 488-490.
9. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960-1963.
10. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010; 363: 1189-1190.
11. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520-8530.
12. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
13. Tefferi A. Myelofibrosis with Myeloid Metaplasia. N Engl J Med 2000; 342: 1255-1265.
14. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005; 105: 973-977.
15. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
16. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
17. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132.
18. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979; 43: 185-190.
19. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010; 85: 62-69.
20. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: Literature review and discussion. Eur J Haematol 2009; 82: 329-338.
21. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011; 29: 3179-3184.
22. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: A distinct entity? Leuk Res 2001; 25: 829-838.
23. Orazi A, O'Malley DP, Jiang J, et al. Acute panmyelosis with myelofibrosis: An entity distinct from acute megakaryoblastic leukemia. Mod Pathol 2005; 18: 603-614.
24. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
25. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708.
26. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010; 115: 496-499.
27. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2011; 25: 82-88.
28. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2009; 85: 14-17.
29. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2011; 96: 167-170.
30. Patnaik MM, Caramazza D, Gangat N, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010; 84: 105-108.
31. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
32. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% two-year mortality in primary myelofibrosis: A Mayo Clinic study of 884 karyotypically-annotated patients. Blood 2011.
33. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105-109.
34. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761.
35. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114: 1477-1483.
36. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
37. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2011.
38. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011.
39. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 2011.
40. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
41. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009; 27: 5587-5593.
42. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008; 112: 2726-2732.
43. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116: 2857-2858.
44. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
45. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
46. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13: 377-383.
47. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117: 288-296.
48. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106: 1974-1984.
49. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-2541.
50. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158-1164.
51. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27: 4760-4766.
52. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009; 83: 154-155.
53. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21: 1827-1828.
54. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol 2010; 89: 1233-1237.
55. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001; 97: 1896.
56. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
57. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
58. Deeg HJ, Appelbaum FR. Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. Blood 2011; 117: 7185.
59. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
60. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563-4569.
61. Verstovsek S, Kantarjian H, Mesa RA, et al. Long-term follow up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: Durable clinical, functional and symptomatic responses with improved hematological safety. ASH Annu Meeting Abstr. 2009; 114: 756.
62. Verstovsek S, Passamonti F, Rambaldi A, et al. A Phase 2 Study of INCB018424, An oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. ASH Annu Meeting Abstr 2009; 114: 311.
63. Pardanani AD, Gotlib JR, Jamieson C, et al. A Phase I Evaluation of TG101348, a selective jak2 inhibitor, in myelofibrosis: Clinical response is accompanied by significant reduction in JAK2V617F allele burden. ASH Annu Meeting Abstr 2009; 114: 755.
64. Vannucchi AM, Guglielmelli P, Lupo L, et al. A Phase 1/2 Study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: Final results. ASH Annu Meeting Abstr 2010; 116: 314.
65. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446-455.
66. DeAngelo DJ, Spencer A, Fischer T, et al. Activity of oral panobinostat (LBH589) in patients with myelofibrosis. ASH Annu Meeting Abstr 2009; 114: 2898.
67. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011; 25: 301-304.
68. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010; 85: 129-130.
69. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
70. Tefferi A, Litzow M, Pardanani A. Long-term outcome of ruxolitinib therapy in myelofibrosis. N Engl J Med 2011; 365: 1455-1457.
71. Verstovsek S, Mesa RA, Gotlib JR, et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J Clin Oncol 2011; 29(suppl; abstr 6500).
72. Harrison CN, Kiladjian JJ, Al-Ali HK, et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol 2011; 29(suppl; abstr LBA6501).
73. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
74. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115: 1131-1136.
75. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011; 118: 2069-2076.
76. Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol 2010; 85: 192-199.
77. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-370.
78. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630- 3636.
79. Doki N, Irisawa H, Takada S, Sakura T, Miyawaki S. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Int Med 2007; 46: 187-190.
80. Angermayr B, Cejna M, Schoder M, et al. Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood 2002; 99: 4246-4247.
81. Belohlavek J, Schwarz J, Jirasek A, Krajina A, Polak F, Hruby M. Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS). Wien Klin Wochenschr 2001; 113: 208-211.
82. Tanaka N, Yamakado K, Kihira H, Hashimoto A, Murayama T, Takeda K. Re: Transjugular intrahepatic portosystemic shunt for intractable esophageal-gastric variceal hemorrhage in a patient with idiopathic myelofibrosis. Cardiovasc Intervent Radiol 2000; 23: 491-492.
83. Alvarez-Larran A, Abraldes JG, Cervantes F, et al. Portal hypertension secondary to myelofibrosis: A study of three cases. Am J Gastroenterol 2005; 100: 2355-2358.
84. Wiest R, Strauch U, Wagner H, et al. A patient with myelofibrosis complicated by refractory ascites and portal hypertension: To tips or not to tips? A case report with discussion of the mechanism of ascites formation. Scand J Gastroenterol 2004; 39: 389-394.
85. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000; 95: 2226-2233.
86. Feldman LS, Demyttenaere SV, Polyhronopoulos GN, Fried GM. Refining the selection criteria for laparoscopic versus open splenectomy for splenomegaly. J Laparoendosc Adv Surg Tech A 2008; 18: 13-19.
87. Iwase K, Higaki J, Mikata S, et al. Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. Surg Laparosc Endosc Percutan Tech 1999; 9: 197-202.
88. Hiatt JR, Gomes AS, Machleder HI. Massive splenomegaly. Superior results with a combined endovascular and operative approach. Arch Surg 1990; 125: 1363-1367.
89. Hocking WG, Machleder HI, Golde DW. Splenic artery embolization prior to splenectomy in end-stage polycythemia vera. Am J Hematol 1980; 8: 123-127.